English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Latest Press Releases
Tuesday, December 3, 2024
从亚洲到全球 顺丰控股开启新一轮价值跃升
10:00 HKT/SGT
Fujitsu entrepreneurship program spins out first start-up company
09:48 HKT/SGT
eBRAM Partners with Agency for Volunteer Service to Launch 'Pro-Bono Online Mediation Scheme for Water Seepage Disputes'
09:26 HKT/SGT
一邦携手义务工作发展局推出「渗漏纠纷义务网上调解服务」
09:21 HKT/SGT
一邦攜手義務工作發展局推出「滲漏糾紛義務網上調解服務」
09:15 HKT/SGT
Macau LRT Seac Pai Van and Hengqin Extension Lines Begin Commercial Operations
07:30 HKT/SGT
15 Companies Pitch Their Capabilities at GA-ASI's Blue Magic Netherlands
07:00 HKT/SGT
Advancing the Belt and Road Initiative: The Kyrgyz Republic Ministry of Finance's First Promotional Seminar and Non-Deal Roadshow Successfully Held
00:45 HKT/SGT
共建一帶一路:吉爾吉斯斯坦國家財政部首場推介會暨非交易性路演成功舉行
00:15 HKT/SGT
共建一带一路:吉尔吉斯斯坦国家财政部首场推介会暨非交易性路演成功举行
00:10 HKT/SGT
Monday, December 2, 2024
#CTS24 Concluded Last Week, Advancing Net-Zero Goals and Sustainable Solutions
22:50 HKT/SGT
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
22:30 HKT/SGT
Honda Introduces AI-powered Social Robot, Haru, to University Hospital in Spain
22:08 HKT/SGT
MeAI Sees Strong Support from Top Launchpad CEOs Following Sold-Out IDO
22:00 HKT/SGT
DENSO to Exhibit at "Automechanika Dubai 2024"
21:38 HKT/SGT
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
21:30 HKT/SGT
Fujitsu expands global strategic collaboration agreement with AWS to promote customer digital transformation across industries
21:07 HKT/SGT
MeAI Sees Strong Support from Top Launchpad CEOs Following Sold-Out IDO
21:00 HKT/SGT
康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利
20:49 HKT/SGT
康哲药业获得治疗痛风及高尿酸血症的1类新药独家商业化权利
20:37 HKT/SGT
三菱重工、マカオLRT「石排湾」および「横琴」の両延伸線が営業運転を開始
16:30 HKT/SGT
CleverTap Report: 46% of Product Managers Cite Resource Limitations as Top Barrier to App and Web Experimentation
16:30 HKT/SGT
富士通、AWSとのグローバルな戦略的協業契約を拡大し、お客様のデジタルトランスフォーメーションを加速
13:30 HKT/SGT
最新のAIによる⽇本株の銘柄スクリーニングアプリ『AI銘柄スクリーナー』の無料β版をリリース
12:15 HKT/SGT
MHI Receives Order to Supply 24 MOX Fuel Assemblies for Unit 3 of Ikata Nuclear Power Station, Shikoku Electric Power Co. Inc.
11:55 HKT/SGT
MHI Receives Order from Taiwan High Speed Rail Corporation for Trackwork and Core System for New Rolling Stock Inspection Shop in Zuoying Depot
11:21 HKT/SGT
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
10:34 HKT/SGT
雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德(VELSIPITY(R))
10:30 HKT/SGT
云顶新耀宣布中国香港卫生署正式受理伊曲莫德(VELSIPITY(R))
10:25 HKT/SGT
ULVAC Launches New Deposition System for Semiconductor Applications: Model "ENTRON-EXX"
08:10 HKT/SGT
Sunday, December 1, 2024
GoKardz Launches Enterprise Module to Revolutionize Digital Business Card Management Empowering Businesses with Comprehensive Digital Networking Solutions
13:00 HKT/SGT
Saturday, November 30, 2024
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
21:08 HKT/SGT
華領醫藥宣佈成功完成在美國開展的第二代葡萄糖激酶激活劑I期臨床研究
20:56 HKT/SGT
华领医药宣布成功完成在美国开展的第二代葡萄糖激酶激活剂I期临床研究
20:46 HKT/SGT
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
20:34 HKT/SGT
華領醫藥宣佈成功完成在中國香港開展的SENSITIZE研究
20:11 HKT/SGT
华领医药宣布成功完成在中国香港开展的SENSITIZE研究
19:58 HKT/SGT
把握政策机遇 推进高质量及可持续发展战略
13:40 HKT/SGT
把握政策機遇 推進高質量及可持續發展戰略
13:27 HKT/SGT
Friday, November 29, 2024
Edvantage Group Announces FY2024 Annual Results
22:14 HKT/SGT
中滙集團公佈2024財年全年業績
21:49 HKT/SGT
The Hong Kong Institute of Directors Announces Winners
21:06 HKT/SGT
香港董事学会公布2024年董事嘉奖系列得主
20:39 HKT/SGT
领跑行业 顺丰控股港股IPO助力国际化发展提速
20:10 HKT/SGT
香港董事學會公佈2024年董事嘉獎系列得主
18:42 HKT/SGT
 ACN Search:
 
Andy Pitre, EVP of Product, HubSpot, launching Breeze at INBOUND 2024
 
Daily Newsletter
Browse Press Releases
Press Releases by Industry »
Press Releases by Language »
Multimedia Press Releases »
Events newsroom »
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575